Fatty Liver Disease (MASLD): The Metabolic Warning Sign of Insulin Resistance

David S. Klein, MD FACA FACPM
6 days ago
3 min read

Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly called fatty liver, is not a liver problem alone—it is a systemic marker of insulin resistance. Often silent for years, MASLD signals elevated cardiometabolic, cognitive, and longevity risk long before abnormal liver enzymes or diabetes appear.

Introduction: When the Liver Becomes the Canary

Fatty liver disease is frequently discovered incidentally—on imaging, during routine labs, or after years of metabolic dysfunction have already taken hold.

What is often missed is that MASLD is not primarily a hepatic disorder. It is a metabolic signal, reflecting chronic insulin resistance, excess insulin exposure, and impaired energy handling across the body.

In many patients, fatty liver is the earliest visible organ damage caused by insulin resistance—appearing well before diabetes, cardiovascular disease, or cognitive decline.

What Is MASLD (Formerly NAFLD)?

MASLD—metabolic dysfunction–associated steatotic liver disease—describes excess fat accumulation in the liver unrelated to alcohol use, viral hepatitis, or medications.

It represents a spectrum:

Simple hepatic steatosis
Steatohepatitis (MASH)
Fibrosis
Cirrhosis and hepatocellular carcinoma

Crucially, progression is driven not by calories alone, but by insulin resistance and chronic hyperinsulinemia.

How Insulin Resistance Drives Fatty Liver

The liver sits at the center of glucose and lipid metabolism. When insulin resistance develops:

Insulin fails to suppress hepatic glucose production
Lipolysis increases, flooding the liver with free fatty acids
De novo lipogenesis accelerates
Mitochondrial fat oxidation becomes impaired

The result is progressive fat deposition within hepatocytes, even when fasting glucose and HbA1c remain “normal.”

MASLD is therefore best understood as hepatic insulin resistance made visible.

Medical diagram showing insulin resistance driving fatty liver disease (MASLD) via hyperinsulinemia, increased fat delivery to the liver, de novo lipogenesis, and mitochondrial dysfunction. — Insulin Resistance and Fatty Liver Disease (MASLD) Pathway

Why Liver Enzymes Often Miss the Diagnosis

A common misconception is that normal AST and ALT exclude fatty liver. In reality:

Many patients with MASLD have normal liver enzymes
Enzymes fluctuate and lag behind pathology
Fibrosis can progress silently

Relying solely on liver enzymes delays diagnosis until irreversible injury may already be present.

MASLD and Cardiovascular Disease Risk

Patients with fatty liver are significantly more likely to die from cardiovascular disease than from liver failure.

MASLD is strongly associated with:

Atherogenic dyslipidemia
Endothelial dysfunction
Systemic inflammation
Increased coronary plaque burden

In this sense, fatty liver acts as a cardiovascular risk amplifier, not merely a coincidental finding.

MASLD, the Brain, and Accelerated Aging

Emerging data link fatty liver disease to:

Cognitive decline
White matter changes
Increased dementia risk

The shared mechanism is insulin resistance–driven inflammation, vascular dysfunction, and impaired energy metabolism.

From a longevity perspective, MASLD reflects accelerated metabolic aging, not an isolated organ problem.

Diagram showing how fatty liver disease (MASLD) contributes to heart disease and brain injury via insulin resistance, systemic inflammation, oxidative stress, and vascular dysfunction. — Fatty Liver Disease (MASLD) and Heart–Brain Risk | Stages of Life Medical Institute

Identifying MASLD Early: What Matters Clinically

Early detection focuses on metabolic context, not just liver-specific labs.

Key considerations include:

Waist circumference and body composition
Triglyceride-to-HDL ratio
Fasting insulin or HOMA-IR
Imaging evidence of hepatic steatosis
Coexisting insulin resistance features

When fatty liver is identified, it should trigger systemic metabolic evaluation, not reassurance.

Clinical Implications: Treat the Metabolism, Not Just the Liver

There is no medication that “treats fatty liver” in isolation.

Effective intervention targets:

Reduction of insulin demand
Restoration of muscle insulin sensitivity
Improvement in mitochondrial function
Reduction in hepatic fat flux

When insulin resistance improves, liver fat often follows.

Illustration showing reversal of fatty liver disease (MASLD) through improved insulin sensitivity, including reduced insulin demand, enhanced muscle glucose uptake, improved mitochondrial function, and restoration of liver health. — Reversing Fatty Liver Disease (MASLD) by Improving Insulin Sensitivity | Stages of Life Medical Institute

Final Perspective: Fatty Liver Is an Early Warning—Not a Benign Finding

MASLD is one of the earliest, most visible manifestations of insulin resistance.

Recognizing it as a metabolic warning sign—rather than a benign imaging finding—creates an opportunity to intervene before diabetes, cardiovascular disease, cognitive decline, and accelerated aging develop.

Have you been told you have fatty liver—or borderline liver labs?

This may be an early sign of insulin resistance and increased cardiometabolic risk.

👉 Schedule a comprehensive metabolic evaluation at Stages of Life Medical Institute to assess insulin sensitivity, liver health, and long-term disease risk before irreversible damage occurs.

REFERENCES

The medical references cited in this article are provided for educational purposes only and are intended to support general scientific discussion. They are not a substitute for individualized medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with a qualified healthcare professional who can account for a patient’s unique medical history, medications, and circumstances.

Subscribe to our Blog